Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT07011017
Starting soon Observational

Sexual Health of Sub-Saharan African Migrant Women Recently Diagnosed With HIV in Île-de-France: Missed Opportunities for Prevention

NCT07011017 · tracked via the Priya Life Science France tracker
Sponsor
Centre Hospitalier de Saint-Denis
Phase
Observational
Started
2025-06-15
Last updated
2025-06-08

Condition(s) studied

HIV InfectionsSexual HealthMigrantsWomen's HealthHealth Services AccessibilitySub-Saharan AfricaRisk-TakingVulnerable Populations

Study summary

This study looks at the sexual health of women from Sub-Saharan Africa who recently found out they have HIV after arriving in Île-de-France. It aims to understand their risk factors and identify missed chances for HIV testing and prevention. The goal is to improve care and support for these women by learning more about their experiences and the challenges they face.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Sub-Saharan African migrant women recently diagnosed with HIV (from 2021 onward) * HIV diagnosis made on French territory * Aged 18 years or older Exclusion Criteria: * Inability to inform the patient about the study due to a language barrier or other obstacle * HIV diagnosis made before 2021 * HIV diagnosis made in the country of origin * Under 18 years of age

Primary outcome measure(s)

  • Description of sexual health characteristics (e.g., history of sexually transmitted infections, contraceptive use, number and type of sexual partners, presence of transactional sex, and access to sexual health services) in Sub-Saharan African migrant wom — enrollment - 5 months

Trial sites (1)

FacilityCityRegionStatus
France Saint-Denis France

More Centre Hospitalier de Saint-Denis trials in France

Assessment of Prolonged Pain in Infants With Excessive Crying: Contribution of Infrared Thermal Imaging - The NEOTHERM Pilot Study Starting soon
Clinical and Biological Signs of Dapagliflozin Overdose in ICU Patients With Metformin Poisoning Recruiting
Evaluate a Local Program to Reduce the Risky Use of Screens by Children Under 3, Based on the Experience of Parents Who Successfully Stopped This Exposure. Starting soon
Requests for Voluntary Termination and Medical Termination of Pregnancy for Maternal, Psychological or Social Reasons At the Women's Center ( La Maison Des Femmes) in Saint-Denis : Active, not recruiting
Monotherapy vs Combination Therapy for Bone Infections Caused by Pseudomonas Aeruginosa Recruiting

Other trials for the same condition

Cohort IMEA 070 -Lenacapavir Compassional Active, not recruiting
Study of Autophagy and the Effects of GALIG Gene Products in HIV-1 Infected Patients Who Are Under Antiretroviral Therapy Since Primary-infection, Chronic Phase, or Never Treated. Recruiting
Microbiota Footprint and Frailty Phenotype in Virologically Suppressed People Living With HIV Recruiting
Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults Active, not recruiting
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study) Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07011017 on ClinicalTrials.gov ↗ ← All trials in France